Skip to main content
usedby
Search tools, companies

How Boehringer Ingelheim uses Owkin

As published on owkin.com, September 2026. Checked by usedby on Oct 9, 2026.

What happened

Boehringer Ingelheim licenses Owkin's K Pro AI Scientist along with multimodal oncology data, and new immunology data generated by Owkin, to speed up discovery across multiple indications. Its teams use K Pro as a single environment to query the data and run reproducible analyses for hypothesis generation, testing and prioritization.

Summary written by usedby from the source page, in English. The figures are those of Owkin and Boehringer Ingelheim, not ours.

Boehringer Ingelheim’s teams will access and analyze this data through K Pro, which provides a single environment to interrogate data and run reproducible analyses. K Pro’s reasoning capabilities support human-led analysis and self-driven campaigns for hypothesis generation, testing and prioritization.

From the page. owkin.com

What the story claims, and what we checked

What we compared with the page.

  • The passage quoted aboveCheckedCopied word for word from the page, near the name of Boehringer Ingelheim.
  • The publication dateCheckedRead from the page’s own metadata, never guessed.
  • Boehringer Ingelheim uses OwkinCheckedConfirmed line.
  • The result itselfNot checkedWe quote it; we did not measure it.

Same company, same tool or same industry.

1,700CCAD prostate cancer patients' data integratedCleveland Clinic Abu Dhabi uses Owkin. Another customer of OwkinSanofi uses OwkinAnother customer of OwkinBristol Myers Squibb uses OwkinAnother customer of Owkin